Vivoryon Therapeutics Completes Share Capital Reduction
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), a prominent clinical-stage biotechnology firm, has successfully executed a notable share capital reduction. This initiative involves lowering the nominal value of its shares from EUR 1.00 to EUR 0.01, a strategic move aimed at boosting financial flexibility and attracting new investment opportunities.
Approval and Implementation
The reduction was approved during the Company’s recent annual general meeting and represents a strategic decision backed by Vivoryon’s Board of Directors. They acknowledged the need to adjust their capital structure to support their ambitious growth objectives. Following Dutch regulations, a formal creditor opposition procedure was carried out, and since no objections were raised, the capital reduction was effectively implemented.
Strengthening Financial Position
This nominal value reduction is crucial for Vivoryon Therapeutics. It is expected to streamline the share structure and enhance the Company’s ability to raise capital for potential mergers and acquisitions. Additionally, this adjustment allows the Company to offer equity awards, which will motivate management and employees while improving its overall equity profile.
Current Capital and Share Structure
After the reduction, each share now has a nominal value of EUR 0.01. Despite this change, the total number of issued ordinary shares remains at 26,066,809. The reduction of EUR 0.99 per share positively impacts the Company’s distributable reserves, which is vital for future growth initiatives.
About Vivoryon Therapeutics
Vivoryon Therapeutics focuses on developing innovative small molecule-based therapies aimed at diseases linked to pathological protein alterations. Their research primarily targets conditions such as Alzheimer’s disease and fibrotic disorders, including those related to kidney issues, while also making strides in cancer therapeutics. The company is committed to utilizing its expertise in post-translational modifications to create impactful and transformative treatments.
Contact Information for Stakeholders
For any further inquiries, stakeholders can get in touch with:
Investor Contact:
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Tel: +49 (0)345 555 99 30
Email: IR@vivoryon.com
Media Contact:
Trophic Communications
Valeria Fisher
Tel: +49 175 8041816
Email: vivoryon@trophic.eu
Frequently Asked Questions
What is the recent capital reduction by Vivoryon Therapeutics?
The company has reduced the nominal value of its shares from EUR 1.00 to EUR 0.01 to improve its financial flexibility.
Why was the capital reduction implemented?
This change aims to attract new financing, facilitate M&A opportunities, and incentivize management and employees through equity awards.
How many shares are currently in circulation?
Vivoryon Therapeutics currently has 26,066,809 ordinary shares issued.
What impact does the capital reduction have on the company's reserves?
The EUR 0.99 per share reduction has been added to the Company's distributable reserves, strengthening its financial position.
Who can I contact for more information about Vivoryon's developments?
For investor relations, you can contact Dr. Manuela Bader at IR@vivoryon.com. For media inquiries, reach out to Valeria Fisher at vivoryon@trophic.eu.
